Integration of Trastuzumab, with or without Pertuzumab, into Perioperative Chemotherapy of HER2-Positive Stomach Cancer: The INNOVATION Trial (EORTC-1203-GITCG)

Publisher： Karger

E-ISSN： 2296-5262|39|3|153-155

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.39, Iss.3, 2016-03, pp. : 153-155

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Combination of Trastuzumab and Triple FLOT Chemotherapy (5-Fluorouracil/Leucovorin, Oxaliplatin, and Docetaxel) in Patients with HER2-Positive Metastatic Gastric Cancer: Report of 3 Cases

By  

Oncology Research and Treatment, Vol. 35, Iss. 9, 2012-08 ,pp. : 505-508

Karger

Access to resources Recommend Favorite

Safety and Efficacy of Trastuzumab Every 3 Weeks Combined with Cytotoxic Chemotherapy in Patients with HER2-Positive Recurrent Breast Cancer: Findings from a Case Series

By  

Oncology Research and Treatment, Vol. 28, Iss. 11, 2005-10 ,pp. : 558-564

Karger

Access to resources Recommend Favorite

Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer

By Boyraz Baris   Sendur Mehmet A.N.   Aksoy Sercan   Babacan Taner   Roach Emir C.   Kizilarslanoglu Muhammet C.   Petekkaya Ibrahim   Altundag Kadri  

Current Medical Research and Opinion, Vol. 29, Iss. 4, 2013-04 ,pp. : 405-414

Informa Healthcare

Access to resources Recommend Favorite

Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer

By Haq Bushra   Geyer Charles E  

Women's Health, Vol. 5, Iss. 2, 2009-03 ,pp. : 135-147

Future Medicine

Access to resources Recommend Favorite

Trastuzumab as Single Agent Therapy for HER2-Positive Metastatic Breast Cancer

By  

Oncology Research and Treatment, Vol. 33, Iss. 8-9, 2010-07 ,pp. : 420-421

Karger

Access to resources Recommend Favorite